Entain Plc (OTCMKTS:GMVHF – Get Rating) was the target of a large increase in short interest in December. As of December 30th, there was short interest totalling 947,000 shares, an increase of 5.5% from the December 15th total of 898,000 shares. Based on an average trading volume of 1,000 shares, the short-interest ratio is presently 947.0 days.
Entain Price Performance
Shares of GMVHF opened at $18.57 on Wednesday. Entain has a one year low of $11.70 and a one year high of $22.65. The stock’s fifty day moving average is $16.75 and its 200-day moving average is $15.07.
Analysts Set New Price Targets
Several equities research analysts recently issued reports on the company. Redburn Partners assumed coverage on Entain in a research report on Wednesday, October 12th. They set a “neutral” rating on the stock. Barclays dropped their price target on Entain from GBX 1,950 ($24.14) to GBX 1,450 ($17.95) in a research report on Wednesday, October 19th. Jefferies Financial Group dropped their target price on Entain from GBX 2,025 ($25.07) to GBX 1,900 ($23.52) in a research report on Thursday, October 13th. Deutsche Bank Aktiengesellschaft increased their target price on Entain from GBX 1,800 ($22.29) to GBX 1,892 ($23.42) in a research report on Wednesday, January 18th. Finally, Berenberg Bank dropped their target price on Entain from GBX 2,000 ($24.76) to GBX 1,930 ($23.90) in a research report on Wednesday, January 18th.
About Entain
Entain Plc engages in the provision of online sports betting and gaming. It operates through the following business segments: Online, UK Retail, European Retail, Corporate, and Other. The Other segment comprises betting and gaming activities from online and mobile operations, Sports Brands include bwin, Coral, Crystalbet, Eurobet, Ladbrokes and Sportingbet; Gaming Brands include Casino Club, Foxy Bingo, Gala, Gioco Digitale, partypoker and PartyCasino.
Further Reading
- Get a free copy of the StockNews.com research report on Entain (GMVHF)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab’s First U.S. Launch Send Stock Into Stratosphere?
- When Will Crane Holdings Take Flight?
Receive News & Ratings for Entain Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entain and related companies with MarketBeat.com's FREE daily email newsletter.